| pubmed-article:9198235 | pubmed:abstractText | FTA is a promising adjunct treatment in many fields of surgery, mainly in patients with acquired and congenital bleeding disorders or in procedures with high risk of postoperative bleeding or leaking of air, blood, fluids. Numerous report exist for variety of indications, however, very few are well controlled and conclusive. There is controversy and contradicting data that stem from variability in FTA formulation the selection and design of the operative indication the methodology of application including the application devices and the skills of the surgeon. Understanding of all these differences and the requirements for the certain indication are important for the successful use of FTA. It is important to remember that FTA is a blood product and even with more than one viral inactivation techniques there should have a clear indication for its use. If no clinically important benefit is proven for a certain indication it means that contraindication exists. | lld:pubmed |
